Skip to Content

Miraxion Approval Status

FDA Approved: No
Brand name: Miraxion
Generic name: eicosapentaenoic acid (EPA)
Company: Amarin Corporation plc
Treatment for: Huntington's Disease

Miraxion (eicosapentaenoic acid) is a phospholipid-based TLA2 inhibitor in development for the treatment of Huntington’s disease.

Development Status and FDA Approval Process for Miraxion

DateArticle
Nov 19, 2007Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide